高级检索
当前位置: 首页 > 详情页

An antioxidant metal-organic framework with functional coatings for oral anti-TNF-α antibody delivery in inflammatory bowel disease treatment

文献详情

资源类型:
Pubmed体系:
机构: [1]UCLouvain, Universite catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, 1200 Brussels, Belgium. [2]EM-platform, VIB Bio Imaging Core, KU Leuven, Campus Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. [3]Department of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. [4]WEL Research Institute, avenue Pasteur, 6, 1300 Wavre, Belgium.
出处:
ISSN:

关键词: Oral biomacromolecule delivery Oral antibody Metal-organic framework Anti-inflammatory treatment Inflammatory bowel disease

摘要:
Oral biomacromolecule delivery is considered a promising alternative for patients who must receive long-term invasive injections, providing better patient compliance. However, it still faces great challenges due to the harsh gastrointestinal environment, including instability and poor intestinal absorption. Here, we report an antioxidant moiety (manganese ion, Mn4+)-assembled metal-organic framework (MOF) presenting functionalized coatings consisting of an inner layer of hyaluronic acid-polyethylene glycol and an outer layer of Eudragit® S100 for enhanced colon-targeted delivery of an anti-mouse tumor necrosis factor-alpha (TNF-α) antibody via oral route. The developed anti-TNF-α antibody-MOF system presented gastric resistance, enhanced targeting of the inflamed intestine, and antioxidant activity. In acute inflammatory bowel disease (IBD) models, the therapeutic effect of the oral anti-TNF-α antibody-MOF system was similar, or even better, than that of intravenous injections at the same antibody dose, with superior antioxidant and mucosal healing capacities. We also demonstrated that in a chronic murine colitis model, the oral anti-TNF-α antibody-MOF system significantly reduced the pathological features of the disease, especially the levels of proinflammatory factors and oxidation markers, which did not differ significantly from those in healthy mice. Overall, this study provides a promising strategy for the oral delivery of antibodies in IBD treatment.Copyright © 2025 The Authors. Published by Elsevier B.V. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 1 区 医学
小类 | 1 区 药学 2 区 化学:综合
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 药学 2 区 化学:综合
第一作者:
第一作者机构: [1]UCLouvain, Universite catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, 1200 Brussels, Belgium.
通讯作者:
通讯机构: [1]UCLouvain, Universite catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, 1200 Brussels, Belgium. [4]WEL Research Institute, avenue Pasteur, 6, 1300 Wavre, Belgium.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:65780 今日访问量:0 总访问量:5151 更新日期:2025-12-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号